ALLO
Allogene TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bullish re-rating depends on the June 2026 ALLO-329 data and the longer ALPHA3 path validating that the platform can still produce differentiated clinical signals after the Overland restructuring. The balance-sheet update is constructive, but the upside case is still primarily clinical rather than financial.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
ALPHA3 remains a longer-dated binary; weak durability or futility signals would reset the story.
Momentum
96
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.10 · Bull $4.00 · Bear $0.90
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.38
Why
Momentum96 · Δ7d -
Value41 · Δ7d +0.1
Sentiment58 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
96
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
58
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 96.4 / Value 41.1 / Sentiment 58.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$742.08M
Beta
0.60
Shares Out
224.73M
P/E (TTM) · Derived
-2.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.50
Rev YoY
-100.0%
EPS YoY
+41.2%
Gross Margin
-
Op Margin
-1241814.0%
Net Debt
-$292.48M
Current Ratio
8.19
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology